vs
爱德华生命科学（EW）与Stryker Corporation（SYK）财务数据对比。点击上方公司名可切换其他公司
Stryker Corporation的季度营收约是爱德华生命科学的4.3倍（$7.2B vs $1.6B），爱德华生命科学净利率更高（23.1% vs 11.8%，领先11.3%），爱德华生命科学同比增速更快（16.7% vs 11.4%），过去两年Stryker Corporation的营收复合增速更高（16.9% vs 9.7%）
爱德华生命科学是总部位于美国加利福尼亚州尔湾的医疗科技企业，专注于人工心脏瓣膜及血流动力学监测领域，其研发的Sapien经导管主动脉心脏瓣膜采用牛组织材质，搭配球囊扩张式钴铬合金支架，可通过导管完成植入。
斯特赖克是一款八轮装甲战车，衍生自加拿大LAV III步兵战车，而后者源自瑞士莫瓦格食人鱼系列装甲车。该型战车由加拿大通用动力陆地系统公司为美国陆军生产，制造工厂位于安大略省伦敦市。它默认采用8×4四轮驱动，可切换为8×8全轮驱动模式。
EW vs SYK — 直观对比
营收规模更大
SYK
是对方的4.3倍
$1.6B
营收增速更快
EW
高出5.3%
11.4%
净利率更高
EW
高出11.3%
11.8%
两年增速更快
SYK
近两年复合增速
9.7%
损益表 — Q1 FY2026 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $1.6B | $7.2B |
| 净利润 | $380.7M | $849.0M |
| 毛利率 | 78.0% | 64.5% |
| 营业利润率 | 1.8% | 25.2% |
| 净利率 | 23.1% | 11.8% |
| 营收同比 | 16.7% | 11.4% |
| 净利润同比 | 6.8% | 55.5% |
| 每股收益（稀释后） | $0.66 | $2.20 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收EWSYK
| Q1 26 | $1.6B | — | ||
| Q4 25 | $1.6B | $7.2B | ||
| Q3 25 | $1.6B | $6.1B | ||
| Q2 25 | $1.5B | $6.0B | ||
| Q1 25 | $1.4B | $5.9B | ||
| Q4 24 | $1.4B | $6.4B | ||
| Q3 24 | $1.4B | $5.5B | ||
| Q2 24 | $1.4B | $5.4B |
净利润EWSYK
| Q1 26 | $380.7M | — | ||
| Q4 25 | $91.2M | $849.0M | ||
| Q3 25 | $291.1M | $859.0M | ||
| Q2 25 | $333.2M | $884.0M | ||
| Q1 25 | $358.0M | $654.0M | ||
| Q4 24 | $385.6M | $546.0M | ||
| Q3 24 | $3.1B | $834.0M | ||
| Q2 24 | $366.3M | $825.0M |
毛利率EWSYK
| Q1 26 | 78.0% | — | ||
| Q4 25 | 78.1% | 64.5% | ||
| Q3 25 | 77.8% | 63.6% | ||
| Q2 25 | 77.5% | 63.8% | ||
| Q1 25 | 78.7% | 63.8% | ||
| Q4 24 | 78.9% | 64.9% | ||
| Q3 24 | 80.6% | 64.0% | ||
| Q2 24 | 79.9% | 63.0% |
营业利润率EWSYK
| Q1 26 | 1.8% | — | ||
| Q4 25 | 9.6% | 25.2% | ||
| Q3 25 | 19.8% | 18.7% | ||
| Q2 25 | 26.8% | 18.5% | ||
| Q1 25 | 27.9% | 14.3% | ||
| Q4 24 | 22.6% | 9.0% | ||
| Q3 24 | 25.9% | 19.7% | ||
| Q2 24 | 26.8% | 19.4% |
净利率EWSYK
| Q1 26 | 23.1% | — | ||
| Q4 25 | 5.8% | 11.8% | ||
| Q3 25 | 18.7% | 14.2% | ||
| Q2 25 | 21.7% | 14.7% | ||
| Q1 25 | 25.3% | 11.1% | ||
| Q4 24 | 27.8% | 8.5% | ||
| Q3 24 | 226.7% | 15.2% | ||
| Q2 24 | 26.7% | 15.2% |
每股收益（稀释后）EWSYK
| Q1 26 | $0.66 | — | ||
| Q4 25 | $0.16 | $2.20 | ||
| Q3 25 | $0.50 | $2.22 | ||
| Q2 25 | $0.56 | $2.29 | ||
| Q1 25 | $0.61 | $1.69 | ||
| Q4 24 | $0.65 | $1.41 | ||
| Q3 24 | $5.13 | $2.16 | ||
| Q2 24 | $0.61 | $2.14 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | — | $4.0B |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | — | $22.4B |
| 总资产 | — | $47.8B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资EWSYK
| Q1 26 | — | — | ||
| Q4 25 | $4.2B | $4.0B | ||
| Q3 25 | $3.8B | $3.3B | ||
| Q2 25 | $4.1B | $2.4B | ||
| Q1 25 | $3.9B | $2.3B | ||
| Q4 24 | $4.0B | $3.7B | ||
| Q3 24 | $4.4B | $3.9B | ||
| Q2 24 | $2.0B | $1.9B |
股东权益EWSYK
| Q1 26 | — | — | ||
| Q4 25 | $10.3B | $22.4B | ||
| Q3 25 | $10.2B | $21.8B | ||
| Q2 25 | $10.5B | $21.2B | ||
| Q1 25 | $10.1B | $20.9B | ||
| Q4 24 | $10.0B | $20.6B | ||
| Q3 24 | $9.5B | $20.1B | ||
| Q2 24 | $7.4B | $19.8B |
总资产EWSYK
| Q1 26 | — | — | ||
| Q4 25 | $13.7B | $47.8B | ||
| Q3 25 | $13.3B | $47.1B | ||
| Q2 25 | $13.5B | $46.3B | ||
| Q1 25 | $13.0B | $46.0B | ||
| Q4 24 | $13.1B | $43.0B | ||
| Q3 24 | $13.0B | $43.8B | ||
| Q2 24 | $10.1B | $39.1B |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | — | $2.1B |
| 自由现金流经营现金流 - 资本支出 | — | $1.9B |
| 自由现金流率自由现金流/营收 | — | 26.1% |
| 资本支出强度资本支出/营收 | — | 3.7% |
| 现金转化率经营现金流/净利润 | — | 2.52× |
| 过去12个月自由现金流最近4个季度 | — | $4.3B |
8季度趋势，按日历期对齐
经营现金流EWSYK
| Q1 26 | — | — | ||
| Q4 25 | $450.9M | $2.1B | ||
| Q3 25 | $573.7M | $1.5B | ||
| Q2 25 | $290.2M | $1.1B | ||
| Q1 25 | $280.4M | $250.0M | ||
| Q4 24 | $-127.5M | $1.9B | ||
| Q3 24 | $351.8M | $1.5B | ||
| Q2 24 | $371.5M | $633.0M |
自由现金流EWSYK
| Q1 26 | — | — | ||
| Q4 25 | $353.5M | $1.9B | ||
| Q3 25 | $516.2M | $1.4B | ||
| Q2 25 | $240.9M | $928.0M | ||
| Q1 25 | $224.4M | $127.0M | ||
| Q4 24 | $-177.3M | $1.7B | ||
| Q3 24 | $299.9M | $1.3B | ||
| Q2 24 | $286.1M | $481.0M |
自由现金流率EWSYK
| Q1 26 | — | — | ||
| Q4 25 | 22.5% | 26.1% | ||
| Q3 25 | 33.2% | 22.3% | ||
| Q2 25 | 15.7% | 15.4% | ||
| Q1 25 | 15.9% | 2.2% | ||
| Q4 24 | -12.8% | 25.9% | ||
| Q3 24 | 22.1% | 23.7% | ||
| Q2 24 | 20.9% | 8.9% |
资本支出强度EWSYK
| Q1 26 | — | — | ||
| Q4 25 | 6.2% | 3.7% | ||
| Q3 25 | 3.7% | 3.1% | ||
| Q2 25 | 3.2% | 3.0% | ||
| Q1 25 | 4.0% | 2.1% | ||
| Q4 24 | 3.6% | 4.1% | ||
| Q3 24 | 3.8% | 3.1% | ||
| Q2 24 | 6.2% | 2.8% |
现金转化率EWSYK
| Q1 26 | — | — | ||
| Q4 25 | 4.94× | 2.52× | ||
| Q3 25 | 1.97× | 1.79× | ||
| Q2 25 | 0.87× | 1.26× | ||
| Q1 25 | 0.78× | 0.38× | ||
| Q4 24 | -0.33× | 3.54× | ||
| Q3 24 | 0.11× | 1.77× | ||
| Q2 24 | 1.01× | 0.77× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
EW
暂无分部数据
SYK
| Medical | $1.3B | 18% |
| Endoscopy | $1.1B | 16% |
| Traumaand Extremities | $1.1B | 15% |
| Instruments | $925.0M | 13% |
| Knees | $749.0M | 10% |
| Neuro Cranial | $669.0M | 9% |
| Neurovascular | $539.0M | 8% |
| Hips | $499.0M | 7% |
| Other Orthopaedics | $267.0M | 4% |
| Spine | $8.0M | 0% |
